PRGO - Perrigo Company plc
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Dublin,
Ireland
Type: Equity
PRGO price evolution
PRGO
| (in millions $) | 28 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $542.8 | $658.5 | $751.3 | |
| Short term investments | ||||
| Net receivables | $813.3 | $751.6 | $780 | $739.6 |
| Inventory | $1133.8 | $1116.2 | $1121.3 | $1140.9 |
| Total current assets | $3707.8 | $2959.1 | $2806.4 | $2832.9 |
| Long term investments | ||||
| Property, plant & equipment | $1103.5 | $1112.8 | $1088.1 | $1100 |
| Goodwill & intangible assets | $6008.4 | $6368.4 | $6515.2 | |
| Total noncurrent assets | $7438.2 | $7833.9 | $7976.2 | |
| Total investments | ||||
| Total assets | $11203.2 | $10397.3 | $10640.3 | $10809.1 |
| Current liabilities | ||||
| Accounts payable | $458.5 | $471.5 | $453.7 | $477.7 |
| Deferred revenue | ||||
| Short long term debt | $440.8 | $440.6 | $440.6 | |
| Total current liabilities | $1450.5 | $1488.1 | $1554.5 | $1586.3 |
| Long term debt | $4312.6 | $3616.8 | $3624.9 | $3632.8 |
| Total noncurrent liabilities | $4363.9 | $4398.8 | $4454.9 | |
| Total debt | $4057.6 | $4065.5 | $4073.4 | |
| Total liabilities | $6637.2 | $5852 | $5953.3 | $6041.2 |
| Shareholders' equity | ||||
| Retained earnings | -$2207.7 | -$2186.7 | -$2078.3 | -$2080.3 |
| Other shareholder equity | $9.8 | -$54.2 | -$37.7 | $10.7 |
| Total shareholder equity | $4545.3 | $4687 | $4767.9 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $751.3 | $600.7 | $1864.9 | $641.5 |
| Short term investments | $2.5 | |||
| Net receivables | $739.6 | $738.6 | $652.9 | $1054.2 |
| Inventory | $1140.9 | $1150.3 | $1020.2 | $1200.2 |
| Total current assets | $2832.9 | $2719.9 | $3859.9 | $3133.5 |
| Long term investments | $71.7 | |||
| Property, plant & equipment | $1100 | $1165.4 | $1031 | $1182 |
| Goodwill & intangible assets | $6515.2 | $6779.2 | $5150.8 | $6758.2 |
| Total noncurrent assets | $7976.2 | $8297.4 | $6565.8 | $8354.9 |
| Total investments | ||||
| Total assets | $10809.1 | $11017.3 | $10425.7 | $11488.4 |
| Current liabilities | ||||
| Accounts payable | $477.7 | $537.3 | $411.2 | $543.8 |
| Deferred revenue | ||||
| Short long term debt | $440.6 | $36.2 | $603.8 | $37.8 |
| Total current liabilities | $1586.3 | $1113.6 | $1587.9 | $1382 |
| Long term debt | $3632.8 | $4070.4 | $2916.7 | $3528.3 |
| Total noncurrent liabilities | $4454.9 | $5061.6 | $3686.1 | $4451.3 |
| Total debt | $4073.4 | $4106.6 | $3520.5 | $3566.1 |
| Total liabilities | $6041.2 | $6175.2 | $5274 | $5833.3 |
| Shareholders' equity | ||||
| Retained earnings | -$2080.3 | -$2067.6 | -$1927 | -$1858.1 |
| Other shareholder equity | $10.7 | -$27 | $35.5 | $395 |
| Total shareholder equity | $4767.9 | $4842.1 | $5151.7 | $5655.1 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1082.1 | $1156.9 | ||
| Cost of revenue | $724.4 | $729.6 | ||
| Gross Profit | $357.7 | $427.3 | ||
| Operating activities | ||||
| Research & development | $29 | $29.6 | ||
| Selling, general & administrative | $280.7 | $281.3 | ||
| Total operating expenses | $412.9 | $442.9 | ||
| Operating income | -$55.2 | -$15.6 | ||
| Income from continuing operations | ||||
| EBIT | -$57.7 | -$16.2 | ||
| Income tax expense | -$102.7 | -$26.6 | ||
| Interest expense | $43 | $42.7 | ||
| Net income | ||||
| Net income | $2 | -$32.3 | ||
| Income (for common shares) | $2 | -$32.3 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4655.6 | $4451.6 | $4138.7 | $5063.3 |
| Cost of revenue | $2975.2 | $2996.2 | $2722.5 | $3248.1 |
| Gross Profit | $1680.4 | $1455.4 | $1416.2 | $1815.2 |
| Operating activities | ||||
| Research & development | $122.5 | $123.1 | $122 | $177.7 |
| Selling, general & administrative | $1164.1 | $1097.1 | $1018.4 | $1075.1 |
| Total operating expenses | $1528.5 | $1376.5 | $1005.8 | $1699.8 |
| Operating income | $151.9 | $78.9 | $410.4 | $115.4 |
| Income from continuing operations | ||||
| EBIT | $157.2 | $7.2 | $445.7 | -$18.2 |
| Income tax expense | -$3.9 | -$8.2 | $389.6 | $13.2 |
| Interest expense | $173.8 | $156 | $125 | $131.2 |
| Net income | ||||
| Net income | -$12.7 | -$140.6 | -$68.9 | -$162.6 |
| Income (for common shares) | -$12.7 | -$140.6 | -$68.9 | -$162.6 |
| (in millions $) | 28 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$108.4 | $2 | -$32.3 | |
| Operating activities | ||||
| Depreciation | $81.9 | $81.4 | $85.9 | |
| Business acquisitions & disposals | $4.4 | |||
| Stock-based compensation | $23 | $15.6 | $10.6 | |
| Total cash flows from operations | $9.5 | -$1.4 | $208.7 | |
| Investing activities | ||||
| Capital expenditures | -$28.4 | -$25.1 | -$28.7 | |
| Investments | ||||
| Total cash flows from investing | $115.9 | -$73.3 | -$23.5 | -$22.8 |
| Financing activities | ||||
| Dividends paid | -$112.9 | -$37.7 | -$37.6 | -$37.6 |
| Sale and purchase of stock | ||||
| Net borrowings | -$9.8 | -$9.8 | -$6.2 | |
| Total cash flows from financing | $543.1 | -$49.8 | -$60.4 | -$44.6 |
| Effect of exchange rate | $2.9 | -$2.1 | -$7.5 | $11.7 |
| Change in cash and equivalents | $712.2 | -$115.7 | -$92.8 | $153 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$12.7 | -$140.6 | -$68.9 | -$162.6 |
| Operating activities | ||||
| Depreciation | $359.5 | $338.6 | $312.2 | $384.8 |
| Business acquisitions & disposals | $4.4 | -$1865.5 | $1421.3 | -$15.9 |
| Stock-based compensation | $68.8 | $54.9 | $60.1 | $58.5 |
| Total cash flows from operations | $405.5 | $307.3 | $156.3 | $636.2 |
| Investing activities | ||||
| Capital expenditures | -$101.7 | -$96.4 | -$152.1 | -$170.4 |
| Investments | -$15 | |||
| Total cash flows from investing | -$77.5 | -$1958.6 | $1275.8 | -$187.8 |
| Financing activities | ||||
| Dividends paid | -$149.7 | -$142.4 | -$129.6 | -$123.9 |
| Sale and purchase of stock | -$164.2 | |||
| Net borrowings | -$30.2 | $604.5 | -$30.6 | $130.9 |
| Total cash flows from financing | -$187.2 | $421.6 | -$178.7 | -$181.1 |
| Effect of exchange rate | $9.8 | -$48.9 | -$15.6 | $19.9 |
| Change in cash and equivalents | $150.6 | -$1278.6 | $1237.8 | $287.2 |
News
Fundamentals
| Market cap | $3.33B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 136.50M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.27 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.56 |
| Quick ratio | 1.77 |